FEATURES OF CARDIOVASCULAR REMODELING AND MODERN APPROACHES TO THERAPY OPTIMIZATION IN PATIENTS WITH HYPERTENSION ASSOCIATED WITH TYPE 2 DIABETES
Keywords:
arterial hypertension, type 2 diabetes, cardiovascular remodeling, Diampa, Prestarium, KhorezmAbstract
Relevance: The combination of arterial hypertension (AH) and type 2 diabetes (T2D) significantly increases the risk of cardiovascular complications, especially in ecologically challenging regions like Khorezm, Uzbekistan. Purpose: To study the mechanisms of cardiovascular remodeling, identify clinical-functional markers, and assess the efficacy of pathogenetically justified therapy. Materials and Methods: A prospective study included 42 patients aged 41-70. ECG, Holter monitoring, echocardiography, ABPM, and laboratory methods were applied. Treatment included empagliflozin (Diampa), perindopril (Prestarium), and Allapinin. Results: Therapy achieved BP control in 78.6% of patients, reduced left ventricular hypertrophy, improved LV ejection fraction, decreased rhythm disturbances, and improved renal function. Conclusion: Combined therapy effectively reduces cardiovascular remodeling severity and complication risks in patients with comorbid AH and T2D.
References
ADA 2024 Standards of Medical Care in Diabetes. Diabetes Care. 2024;47(Suppl 1):S1–S315.
ACC/AHA Task Force on Clinical Practice Guidelines. 2017 Guideline for the Management of High Blood Pressure. Hypertension. 2018;71:e13–e115.
ADVANCE Collaborative Group. Intensive glucose control and vascular outcomes in type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572.
ESC Guidelines on cardiovascular disease prevention in clinical practice: Eur Heart J. 2021;42(34):3227–3337.
Marso S.P., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
UKPDS Group. Tight BP control and complications in type 2 diabetes. BMJ. 1998;317(7160):703–713.
Williams B. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
Zinman B., et al. Empagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
Герасименко Н.Ф., Горбунова Л.П. Коморбидность при ГБ и СД2. Вестник кардиологии. 2021;27(3):24–30.
Сидорова Ю.С., Иванова Т.А. Ремоделирование миокарда при метаболическом синдроме. Рос. кардиол. журн. 2022;31(1):56–62.
